stock.name

Cartesian Therapeutics Inc

RNAC

Market Cap$405.75M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Cartesian Therapeutics IncCartesian Therapeutics Inc-1.60%218%24.1-0.1
$40.00

Target Price by Analysts

66.3% upsideCartesian Therapeutics Target Price DetailsTarget Price
$-8.19

Current Fair Value

134% downside

Overvalued by 134% based on the discounted cash flow analysis.

Share Statistics

Market cap$405.75 Million
Enterprise Value$312.79 Million
Dividend Yield$0.0 (0.0%)
Earnings per Share$-64.73
Beta0.0
Outstanding Shares17,796,053
Avg 30 Day Volume99,688

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-1.59
PEG-0.98
Price to Sales24.06
Price to Book Ratio-3.44
Enterprise Value to Revenue12.07
Enterprise Value to EBIT-3.84
Enterprise Value to Net Income-2
Total Debt to Enterprise0.03
Debt to Equity-0.09

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Cartesian Therapeutics Inc

81 employees
CEO: Carsten Brunn

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...